## FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person <sup>*</sup> Katz Iftah						2. Issuer Name and Ticker or Trading Symbol Protalix BioTherapeutics, Inc. [PLX]									5. Relationship of Reporting Person( (Check all applicable) Director 1			rson(s) to la 10% O		
(Last)	(Fi	rst) (		3. Date of Earliest Transaction (Month/Day/Year) 05/15/2007									X Officer below)	(give title		Other ( below)	specify			
C/O PRO											VP of Operations									
2 SNUNIT ST, SCIENCE PARK, POB 455						4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street)											X Form filed by One Reporting Person									
CARMIEL L3 21000															Form filed by More than One Reporting Person					
(City)	(S	state) (Zip)																		
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																				
1. Title of Security (Instr. 3) 2. Transacti Date (Month/Day						Execution Date,						ities Acquired (A) or d Of (D) (Instr. 3, 4			5. Amount of Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
								Code	v	Amount	(A) or (D) Prio		Price	Reporte Transac	Reported Transaction(s) (Instr. 3 and 4)		r. 4)	(Instr. 4)		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned           (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	if any (		4. Transaction Code (Instr. 8)		n of		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)		10. Ownershij Form: Direct (D) or Indirec (I) (Instr. 4)	Beneficial Ownership	
					Code	v	(A)	(D)	Date Exercisab		Expiration Date	Title	or Nu of	umber						
Stock Options (Right to Buy)	\$4.33	05/15/2007			Α		204,351		(1)	(	05/15/2017	Common Stock	<sup>1</sup> 20	04,351	\$0	204,3	51	D		

## Explanation of Responses:

1. 25% of the options shall vest on March 1, 2008. The remaining 75% of the options shall vest in 12 equal installments at the end of each three month period thereafter.

<u>/s/ Yossi Maimon, Power of</u> <u>Attorney</u> <u>06/13/2007</u>

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.